GenMark Diagnostics Shares Outstanding 2010-2018 | GNMK

GenMark Diagnostics shares outstanding history from 2010 to 2018. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • GenMark Diagnostics shares outstanding for the quarter ending June 30, 2018 were 0.056B, a 15.56% increase year-over-year.
  • GenMark Diagnostics 2017 shares outstanding were 0.051B, a 16.03% increase from 2016.
  • GenMark Diagnostics 2016 shares outstanding were 0.044B, a 4.61% increase from 2015.
  • GenMark Diagnostics 2015 shares outstanding were 0.042B, a 1.96% increase from 2014.
GenMark Diagnostics Annual Shares Outstanding
(Millions of Shares)
2017 51
2016 44
2015 42
2014 41
2013 35
2012 26
2011 17
2010 10
2009 5
GenMark Diagnostics Quarterly Shares Outstanding
(Millions of Shares)
Q2 2018 56
Q1 2018 55
Q4 2017 51
Q3 2017 55
Q2 2017 48
Q1 2017 47
Q4 2016 44
Q3 2016 44
Q2 2016 43
Q1 2016 43
Q4 2015 42
Q3 2015 42
Q2 2015 42
Q1 2015 42
Q4 2014 41
Q3 2014 41
Q2 2014 41
Q1 2014 41
Q4 2013 35
Q3 2013 36
Q2 2013 32
Q1 2013 32
Q4 2012 26
Q3 2012 32
Q2 2012 21
Q1 2012 20
Q4 2011 20
Q3 2011 20
Q2 2011 14
Q1 2011 12
Q4 2010 12
Q3 2010 12
Q2 2010 9
Q1 2010 7
Q4 2009 5
Q3 2009 5
Q2 2009 4
Q1 2009 4
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $0.326B $0.053B
GenMark Diagnostics, Inc. is a molecular diagnostics company focused on developing and commercializing its proprietary eSensor(R) detection technology. The eSensor? XT-8 system is the second generation in GenMark Dx's eSensor? platform, utilizing electrochemical detection technology to detect nucleic acids on a microarray. The XT-8 System enables multiplex detection of DNA and RNA targets. The Company has developed four diagnostic tests for use with its XT-8 System. Its Cystic Fibrosis Genotyping Test, which detects pre-conception risks of cystic fibrosis, and its Warfarin Sensitivity Test, which determines an individual's ability to metabolize the oral anticoagulant warfarin, have received FDA clearance. It has also developed a Respiratory Viral Panel Test, which detects the presence of major respiratory viruses, and a Thrombosis Risk Test, which detects an individual's increased risk of blood clots. GenMark Diagnostics, Inc. is based in Pasadena, California.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $91.495B 21.95
Intuitive Surgical (ISRG) United States $57.358B 56.66
Edwards Lifesciences (EW) United States $30.449B 34.30
Fresenius Medical Care (FMS) Germany $24.786B 17.51
IDEXX Laboratories (IDXX) United States $18.911B 57.47
ABIOMED (ABMD) United States $16.264B 133.24
DexCom (DXCM) United States $11.398B 0.00
Teleflex (TFX) United States $11.146B 26.51
Hologic (HOLX) United States $11.111B 18.90
Varian Medical Systems (VAR) United States $9.538B 24.01
STERIS (STE) United Kingdom $9.020B 24.81
Masimo (MASI) United States $6.006B 39.99
LivaNova (LIVN) United Kingdom $5.520B 32.92
Integra LifeSciences Holdings (IART) United States $5.328B 27.57
Globus Medical (GMED) United States $5.162B 34.34
Penumbra (PEN) United States $4.709B 428.03
Inogen (INGN) United States $4.171B 110.38
Cantel Medical (CMD) United States $3.475B 35.01
Wright Medical Group (WMGI) Netherlands $2.936B 0.00
Halyard Health (AVNS) United States $2.817B 23.18
Integer Holdings (ITGR) United States $2.376B 21.52
Glaukos (GKOS) United States $2.094B 0.00
Opko Health (OPK) United States $2.010B 0.00
Tandem Diabetes Care (TNDM) United States $1.921B 0.00
Mazor Robotics (MZOR) Israel $1.525B 0.00
Nevro (NVRO) United States $1.515B 0.00
AxoGen (AXGN) United States $1.284B 0.00
Luminex (LMNX) United States $1.267B 37.38
K2Ms (KTWO) United States $1.192B 0.00
Tactile Systems Technology (TCMD) United States $1.182B 201.47
CryoLife (CRY) United States $1.176B 103.19
Orthofix (OFIX) United States $1.065B 32.44
Natus Medical (BABY) United States $1.037B 22.00
Accelerate Diagnostics (AXDX) United States $0.906B 0.00
Intersect ENT (XENT) United States $0.855B 0.00
AngioDynamics (ANGO) United States $0.748B 26.16
ViewRay (VRAY) United States $0.714B 0.00
Mesa Laboratories (MLAB) United States $0.699B 43.21
Sientra (SIEN) United States $0.633B 0.00
Pacific Biosciences Of California (PACB) United States $0.578B 0.00
Neuronetics (STIM) United States $0.437B 0.00
OrthoPediatrics (KIDS) United States $0.420B 0.00
Oxford Immunotec Global (OXFD) United Kingdom $0.414B 0.00
Veracyte (VCYT) United States $0.353B 0.00
Quotient (QTNT) Switzerland $0.351B 0.00
Accuray (ARAY) United States $0.312B 0.00
Nuvectra (NVTR) United States $0.296B 0.00
Fluidigm (FLDM) United States $0.294B 0.00
RTI Surgical (RTIX) United States $0.290B 57.13
IRadimed (IRMD) United States $0.277B 99.89
SeaSpine Holdings (SPNE) United States $0.243B 0.00
T2 Biosystems (TTOO) United States $0.207B 0.00
Helius Medical Technologies (HSDT) United States $0.205B 0.00
Invuity (IVTY) United States $0.178B 0.00
Pulse Biosciences (PLSE) United States $0.163B 0.00
RA MEDICAL SYST (RMED) United States $0.162B 0.00
Apollo Endosurgery (APEN) United States $0.135B 0.00
Alphatec Holdings (ATEC) United States $0.133B 0.00
Ekso Bionics Holdings (EKSO) United States $0.123B 0.00
Viveve Medical (VIVE) United States $0.110B 0.00
Second Sight Medical Products (EYES) United States $0.105B 0.00
HTG Molecular Diagnostics (HTGM) United States $0.101B 0.00
Sensus Healthcare (SRTS) United States $0.090B 0.00
EDAP TMS (EDAP) France $0.077B 0.00
Biosig Technologies (BSGM) United States $0.077B 0.00
ConforMIS (CFMS) United States $0.059B 0.00
Restoration Robotics (HAIR) United States $0.056B 0.00
OBALON THERPTCS (OBLN) United States $0.046B 0.00
Neovasc (NVCN) Canada $0.043B 0.00
Vermillion (VRML) United States $0.036B 0.00
Lianluo Smart (LLIT) China $0.035B 0.00
PAVmed (PAVM) United States $0.031B 0.00
Titan Medical (TMDI) Canada $0.028B 0.00
ReWalk Robotics (RWLK) Israel $0.027B 0.00
Dynatronics (DYNT) United States $0.024B 0.00
DarioHealth (DRIO) Israel $0.023B 0.00
ENDRA Life Sciences (NDRA) United States $0.022B 0.00
Presbia (LENS) Ireland $0.021B 0.00
Nanovibronix (NAOV) United States $0.017B 0.00
Microbot Medical (MBOT) United States $0.016B 0.00
Bioanalytical Systems (BASI) United States $0.016B 0.00
Avinger (AVGR) United States $0.013B 0.00
Sunshine Heart Inc (CHFS) United States $0.008B 0.00
Allied Healthcare Products (AHPI) United States $0.008B 0.00
Cesca Therapeutics (KOOL) United States $0.008B 0.00
Atossa Genetics (ATOS) United States $0.008B 0.00
Amedica (AMDA) United States $0.004B 0.00
EnteroMedics (RSLS) United States $0.000B 0.00
Check-Cap (CHEK) Israel $0.000B 0.00